Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial

Psychosomatic Medicine
Lee S CohenM Steiner

Abstract

Better characterization of safety and efficacy of multiple doses of selective serotonin reuptake inhibitors for the treatment of a wider range of symptoms of premenstrual dysphoric disorder (PMDD) will provide clinicians with flexibility to provide symptom relief along with acceptable tolerability. This study was designed to assess the efficacy and tolerability of multiple doses of paroxetine controlled release (CR) in PMDD. In a multicenter (43 outpatient U.S. sites), placebo-controlled trial, 327 females aged 18 to 45 years, with regular menstrual cycles, meeting DSM-IV criteria for PMDD, were randomly assigned to receive paroxetine CR 12.5 mg; paroxetine CR 25 mg; or placebo, once daily, for up to three treatment cycles. The primary efficacy outcome was change from baseline to end point in mean luteal phase Visual Analogue Scale-Mood (irritability, tension, affective lability, depressed mood) score. At end point, subjects treated with paroxetine CR (12.5 mg and 25 mg) demonstrated significant improvement in VAS-Mood scores compared with those who received placebo (paroxetine CR 12.5 mg mean treatment difference vs. placebo, -8.7 mm; 95% CI, -15.7, -1.7; p =.015; paroxetine CR 25 mg mean treatment difference vs. placebo, -12....Continue Reading

References

Dec 1, 1990·The American Journal of Psychiatry·A D Rivera-Tovar, E Frank
Nov 1, 1988·Psychological Medicine·H M McCormackS Sheather
Apr 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E ErikssonC Sundblad
Jun 1, 1996·International Clinical Psychopharmacology·D V SheehanB A Raj
Aug 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C SundbladE Eriksson
Dec 16, 1997·The American Journal of Psychiatry·M OlfsonL Farber
Jul 15, 1999·Journal of Affective Disorders·M SteinerD Grover
Apr 26, 2003·Archives of Women's Mental Health·M SteinerD Stewart

❮ Previous
Next ❯

Citations

Mar 27, 2013·Paediatric Drugs·Andrea J Rapkin, Judith A Mikacich
Oct 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mikael LandénElias Eriksson
Apr 18, 2009·Harvard Review of Psychiatry·Joanne CunninghamElias Eriksson
Sep 18, 2008·Current Opinion in Obstetrics & Gynecology·Andrea J Rapkin, Judith A Mikacich
Feb 28, 2008·International Clinical Psychopharmacology·Kathy Harnett Sheehan, David V Sheehan
Feb 24, 2010·Applied Health Economics and Health Policy·Regina Rendas-BaumGene V Wallenstein
Feb 17, 2010·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Michael NamakaHoward Intrater
Oct 29, 2013·Women's Health·Andrea J Rapkin, Erin I Lewis
Jan 19, 2006·Journal of Women's Health·Meir SteinerKimberly Yonkers
Oct 17, 2007·Journal of Women's Health·Kat Lin, Kurt Barnhart
Sep 26, 2015·Journal of Affective Disorders·Renske C BosmanMarije aan het Rot
Sep 10, 2011·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Federico Rodriguez-PorcelIan A Paul
Jun 10, 2015·Clinical and Experimental Obstetrics & Gynecology·A ImaiH Takagi
Nov 19, 2013·Journal of Dietary Supplements·Kimberly A BrownleyMalcolm N McLeod
Jan 29, 2008·Expert Opinion on Pharmacotherapy·Andrea J Rapkin, Sharon A Winer
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Marianna MazzaPietro Bria
Aug 16, 2005·American Journal of Obstetrics and Gynecology·Meir SteinerElisabeth Van Erp
Jan 1, 2006·Women's Health·Shaila Misri, Kristin Kendrick
Jun 19, 2008·The Annals of Pharmacotherapy·Courtney I JarvisAnna K Morin
Jun 8, 2013·The Cochrane Database of Systematic Reviews·Jane MarjoribanksKatrina Wyatt
Sep 2, 2005·Obstetrics and Gynecology·Kimberly A YonkersAndrea Rapkin
Jan 24, 2008·Journal of Psychiatric Practice·Anita H Clayton
Mar 18, 2008·Journal of Clinical Psychopharmacology·Elias ErikssonHans Nissbrandt
Feb 9, 2007·Expert Review of Neurotherapeutics·Chi-Un Pae, Ashwin A Patkar
Aug 7, 2010·Expert Opinion on Pharmacotherapy·Ellen W Freeman
Dec 13, 2006·British Journal of Anaesthesia·S T YeoA Stewart

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.